Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mikeluna (OPC-1085EL) vs Latanoprost in POAG or Ocular Hypertension
NCT05583474Phase 3Completed
- Sponsor
- Otsuka Holdings
- Start
- Sep 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Mikeluna in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Otsuka Holdings. Started Sep 2022; status: completed.
02
Drugs
Mikeluna
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT05583474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583474.